New Weight-Loss drug AZD5004 tested in chinese adults

NCT ID NCT06988553

Completed Symptom relief Sponsor: Eccogene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called AZD5004 in 45 Chinese adults who were overweight or had obesity, with or without type 2 diabetes. The main goal was to check if the drug is safe and how the body processes it, compared to a placebo. Participants took the drug or a dummy pill, and researchers monitored side effects and drug levels in the blood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OR OVERWEIGHT TYPE 2 DIABETES

Contacts and locations

Locations

General Hospital of Tianjin Medical University

Tianjin, China
Jinan Central Hospital

Jinan, China
Shanghai Pudong New District People's Hospital

Shanghai, China
The Fourth Affiliated Hospital of Harbin Medical University

Ha’erbin, China
The Second People's Hospital of Hefei

Hefei, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.